Avalo Posts Wider Q2 Loss, Positive Phase 2 Data, and Cash Runway Through 2029
AVTX has more than doubled off its 52-week low of $7.87 on light trading volume (0.4× avg).
Summary
Avalo Therapeutics reported a wider Q2 net loss of $36.4M, but ended the quarter with $472.2M in cash, funding operations into 2029. Positive Phase 2 data for lead drug abdakibart supports a Phase 3 program.
Key Events · Earnings and Guidance · AVTX
-
Q2 Net Loss Widens
Net loss of $36.4M vs $20.8M in Q2 2025, driven by a $10M milestone expense for abdakibart's Phase 3 trial and a $6.6M non-cash contingent consideration charge.
-
Cash Runway Extended into 2029
Cash and investments of $472.2M as of June 30, 2026, following a $405M equity offering in May 2026, funds operations into 2029.
-
Positive Phase 2 LOTUS Data
Abdakibart met primary endpoint in Phase 2 LOTUS trial for hidradenitis suppurativa, with 42.5% absolute improvement in HiSCR75 response rate vs placebo (25.6%).
-
Phase 3 Milestone Accrued
$10M development milestone payable to Lilly upon dosing first patient in Phase 3 trial of abdakibart was deemed probable and expensed in Q2.
Analysis · AVTX · Life Sciences
Avalo's Q2 2026 net loss widened to $36.4M from $20.8M a year ago, driven by a $10M milestone expense for abdakibart's Phase 3 trial and a $6.6M non-cash charge from the AlmataBio buyout. The company ended the quarter with $472.2M in cash and investments, extending its runway into 2029. Positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa supports advancement into a registrational Phase 3 program. Insider trading plans were adopted or modified by the CEO and CFO, while the Chief Legal Officer terminated his plan.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVTX was trading at $18.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $996.7M. The 52-week trading range was $7.87 to $24.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.